Nyxoah marked its recent milestones by ringing the Nasdaq Closing Bell, symbolizing the company’s forward momentum as it approaches the potential US market launch of its Genio device for OSA. Summary: Nyxoah SA rang the Nasdaq Closing Bell on Aug 29 to celebrate its … [Read more...]
Nyxoah Appoints New Exec to Lead Expected US Launch of Genio
Summary: Nyxoah SA has appointed Scott Holstine as chief commercial officer to lead the expected US launch of the Genio neurostimulator for obstructive sleep apnea (OSA). The Genio system, which has already received the CE Mark in Europe, is expected to receive FDA approval by … [Read more...]